Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Training cohort will be recruited in the first 24 months of the study period to generate urine metabolomic and proteomic profiles as predictive and prognostic markers.

Validation cohort will be recruited in the next 36 months of the study period.

No intervention required

Yeong Shiau Pu, MD PhD

Chung Hsin Chen, MD PhD

Chung Hsin Chen,, MD PhD

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.

This is a multi-center single-arm translational study where patients with mRCC who are to receive pre-determined IO-based therapy will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are able to predict efficacy and side effects of IO-based therapies. All subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy will be invited and recruited, but those who have received any IO-based therapy before the study can NOT be recruited.

Urine Omics Predicting IO Therapy Responses in mRCC Patients

Urine Metabolomics and Proteomics Profiling to Predict the Responses and Adverse Events of Immuno-Oncology-based Therapy in Patients With Advanced Renal Cell Carcinoma

National Taiwan University Hospital

Prostatic Neoplasms

Genital Neoplasms, Male

Genital Diseases

Genital Diseases, Male

Prostatic Diseases

All Drugs and Chemicals

Immunomodulating Agents

Ttaining chort will be recruited in the first 36 months of the study period to generate the first batch of urine metabolomic and proteomic profiles as predictive and prognostic markers.

Validation cohort will be recruited in the next 24 months of the study period .

Chung-Hsin Chen, MD PhD

Yeong-Shiau Pu, MD PhD

Yeong-Shiau Pu Pu, MD PhD

The study aims to identify potential urine marker metabolites as predictive or prognostic markers for treatment outcomes in patients with prostate cancer.

This is a single-center single-arm translational study where patients with prostate cancer who are about to receive definitive treatments will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study to identify potential metabolite and protein markers that are able to predict responses (including efficacy and side effects) to definitive treatments. All subjects who have received varied treatment before the study can NOT be recruited.

Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

Decipher the Biology of Lethal Prostate Cancer-Using Urine Metabolomics and Proteomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients

Carcinoma, Transitional Cell

Transitional Cell Carcinoma

The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic urothelial carcinoma.

This is a multi-center single-arm translational study where patients with mUC who are about to receive pre-determined IO-based anti-tumor therapy will be invited to participate the study. After signing the approved informed consent, eligible and consenting subjects will donate their fresh urine samples for subsequent untargeted metabolomics and proteomics study via GS-MS/MS and/or LC-MS/MS to identify potential metabolite and protein markers that are able to predict efficacy and side effects of IO-based therapies. All subjects in the first-line, maintenance after 1st line, second-line, or subsequent lines of IO-based therapy will be invited and recruited, but those who have received any IO-based therapy before the study can NOT be recruited.

Urine Omics Predicting IO Therapy Responses in mUC Patients

Urine Metabolomics and Proteomics Profiling to Predict the Responses and Adverse Events of Immuno-Oncology-based Therapy in Patients With Metastatic Urothelial Carcinoma

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Urine Omics Predicting IO Therapy Responses in mRCC Patients	NCT04712305	Metastatic Rena...	No intervention...	20 Years -	National Taiwan University Hospital
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients	NCT03237026	Prostate Cancer	No intervention...	30 Years - 100 Years	National Taiwan University Hospital
Urine Omics Predicting IO Therapy Responses in mUC Patients	NCT04641936	Metastatic Urot...	No intervention...	20 Years -	National Taiwan University Hospital
Urine Omics Predicting IO Therapy Responses in mUC Patients	NCT04641936	Metastatic Urot...	No intervention...	20 Years -	National Taiwan University Hospital

Spots Global Cancer Trial Database for no intervention required